Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin.
Weegink
C J
CJ
Chamuleau
R A
RA
Reesink
H W
HW
Molenaar
D S
DS
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000209:etiology*; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin